Rheumatology Advances in Practice最新文献

{"title":"Representation of underserved communities in non-pharmacological axial spondyloarthritis trials: a scoping review protocol.","authors":"Alan Mathew, Yeliz Prior, Jenni Buckley, Joseph Loades, James A Prior, Jon Packham, Simone Battista","doi":"10.1093/rap/rkag037","DOIUrl":"10.1093/rap/rkag037","url":null,"abstract":"<p><strong>Objectives: </strong>To effectively address the challenges of managing axial spondyloarthritis (axSpA), improving quality of life and reducing healthcare costs, research must consider the influence of social determinants of health and broader contextual factors. These determinants play a fundamental role in shaping individuals' experiences with axSpA non-pharmacological interventions. Underserved communities, which often face systemic barriers related to these determinants, may experience disproportionate burdens and reduced access to effective care. Despite this, there remains a limited understanding of which social determinants of health and their intersections are collected in axSpA research. This protocol aims to outline the methodology for a scoping review to map and identify how underserved communities, social determinants of health and their intersections are represented in axSpA non-pharmacological research.</p><p><strong>Methods: </strong>The Population, Concept and Context framework was used to consider the eligibility criteria for including studies, utilising an iterative process during each stage of article selection, data extraction and reporting. The scoping review will follow the guidance from the JBI. Findings will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews. The PROGRESS-Plus framework will be used to identify and categorise the collected social determinants of health.</p><p><strong>Conclusion: </strong>This review aims to provide an understanding of how social determinants of health and their intersections are collected in non-pharmacological interventions for axSpA, informing future research priorities and promoting inclusive practices. The findings will be disseminated through research publications, including peer-reviewed articles, conference abstracts and presentations and plain-language summaries for a broader audience.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag037"},"PeriodicalIF":2.8,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13185144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147983020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal Behçet-like syndrome as an initial manifestation in myelodysplastic syndrome with double trisomy of chromosomes 8 and 20 and a 20q deletion.","authors":"Megumi Murakami, Kentaro Kuzuya, Masahiro Misago, Yoshinobu Matsuura, Yoshiki Murakami, Dai Aoki, Shinichiro Nakao, Mototoshi Ito, Norihiko Yamaguchi, Hiroyuki Yamane","doi":"10.1093/rap/rkag044","DOIUrl":"10.1093/rap/rkag044","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag044"},"PeriodicalIF":2.8,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scleroderma renal crisis: avoiding the diagnostic pitfalls of an elusive condition.","authors":"Isaac K S Ng, May Shuen Tang, Faith Huiwen See, Jiacai Cho","doi":"10.1093/rap/rkag043","DOIUrl":"10.1093/rap/rkag043","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag043"},"PeriodicalIF":2.8,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral eyelid erythema and oedema accompanied by systemic lupus erythematosus and syndrome of inappropriate antidiuretic hormone secretion.","authors":"Kohei Goda, Takashi Nawata, Mako Yonezawa, Natsumi Nishimura, Masafumi Fujinaka, Masaki Shibuya, Hiroshi Nakamura, Motoaki Sano","doi":"10.1093/rap/rkag040","DOIUrl":"10.1093/rap/rkag040","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag040"},"PeriodicalIF":2.8,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination?","authors":"Hadi Rabee, Arti Mahto","doi":"10.1093/rap/rkag042","DOIUrl":"10.1093/rap/rkag042","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag042"},"PeriodicalIF":2.8,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13082901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of gout in spondyloarthritis.","authors":"Stuart Johnston, Benjamin Zuckerman, Aashmi Sharma, Uazman Alam, Sizheng Steven Zhao","doi":"10.1093/rap/rkag039","DOIUrl":"10.1093/rap/rkag039","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag039"},"PeriodicalIF":2.8,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of the UK Rheumatology Occupational Therapy Capabilities Framework: a national consensus initiative.","authors":"Yeliz Prior, William J Gregory, Simone Battista, Patricia Bisset, Sandi Derham, Dervil M Dockrell, Caroline Livesey, Sandra Lyle, Sushil Munakhya, Rachael Murphy, Gemma O'Callaghan, Katie O'Donnell, Janet Perkins, Claire Pidgeon, Helen Steer, Sally Tuson, Emma Walker, Gemma Williams","doi":"10.1093/rap/rkag038","DOIUrl":"10.1093/rap/rkag038","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the development and national consensus process underpinning the Rheumatology Occupational Therapy Capabilities Framework. This work addresses the absence of a structured framework defining the knowledge, skills and professional behaviours required of the occupational therapy workforce working within rheumatology services managing rheumatic and musculoskeletal diseases and the need for a consistent national reference to support practice, workforce planning and professional development.</p><p><strong>Methods: </strong>A five-stage mixed methods process was adopted between May 2023 and September 2025, beginning with the design of a UK-wide scoping survey of rheumatology occupational therapists. Subsequent stages included expert consultation, alignment with national and international standards, stakeholder review and endorsement by professional bodies.</p><p><strong>Results: </strong>The process achieved national consensus across rheumatology occupational therapists from all four UK nations and resulted in a four-domain, five-level capability framework mapped to NHS Agenda for Change bands and allied health professions practice levels.</p><p><strong>Conclusion: </strong>This study describes a structured national consensus process used to develop and endorse a specialist capability framework for occupational therapy in rheumatology. The five-stage approach achieved formal endorsement from the Royal College of Occupational Therapists and the British Society for Rheumatology and offers a transparent, transferable model for specialist capability framework development across allied health professions.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag038"},"PeriodicalIF":2.8,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13064976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EBV-positive diffuse large B-cell lymphoma with central nervous system involvement in Anti-Mi-2-positive dermatomyositis.","authors":"Shion Kachi, Ran Nakashima, Hiroaki Ito, Ran Fujimoto, Tsuneo Sasai, Mirei Shirakashi, Ryosuke Hiwa, Hideaki Tsuji, Shuji Akizuki, Akira Onishi, Hajime Yoshifuji, Akio Morinobu","doi":"10.1093/rap/rkag041","DOIUrl":"10.1093/rap/rkag041","url":null,"abstract":"","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag041"},"PeriodicalIF":2.8,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13075938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary cystic destruction in systemic sclerosis and antisynthetase syndrome associated non-specific interstitial pneumonitis: a case series of a novel radiological phenotype.","authors":"Matthew Wells, Giles Dixon, Nidhi Bhatt, Jo Hardy, Huzaifa I Adamali, Harsha Gunawardena, John D Pauling, Shaney L Barratt, Anthony Edey","doi":"10.1093/rap/rkag030","DOIUrl":"10.1093/rap/rkag030","url":null,"abstract":"<p><strong>Objectives: </strong>To describe a novel radiographic phenotype of systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) observed within a regional specialist multidisciplinary (MDT) service.</p><p><strong>Methods: </strong>This was a retrospective case series of patients with SARD-ILD complicated by radiographic pulmonary cystic destruction. Cases were identified through review of MDT records from the North Bristol SARD-ILD service. Cases with MDT reported 'cystic changes' were identified and clinico-radio-pathological features reviewed.</p><p><strong>Results: </strong>Five cases of SSc-associated ILD (SSc-ILD) and two cases of antisynthetase syndrome-associated ILD (ASyS-ILD) with cystic changes were identified among a total of 108 SARD-ILD patients. All seven cases presented with radiological patterns of cellular non-specific interstitial pneumonia (NSIP). The median age at diagnosis with SARD was 33 years and six cases had ILD identified within 6 months of SARD diagnosis. The cohort was ethnically diverse, with one ex-smoker. Microcystic destructive changes appeared and progressed within areas of ground glass despite standard-of-care immunomodulation. Changes are radiographically and histologically distinct from traction bronchiolectasis, honeycombing and smoking-related lung disease. Histological specimens were available for two cases confirming fibrotic NSIP, with one including affected tissue demonstrating intimal thickening of the pulmonary vasculature. Over a median follow-up of 49 months, all cases remain alive and transplant free; five fulfilled criteria for progressive disease and six required ambulatory oxygen.</p><p><strong>Conclusions: </strong>This represents the first western cohort describing microcystic destructive pulmonary changes in SSc-ILD and the first report in ASyS-ILD. Systematic case identification is required to determine demographic associations and prognostic implications.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag030"},"PeriodicalIF":2.8,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision on Optimal Combinatorial Therapies in Immune-mediated inflammatory diseases using Systems approaches (DocTIS): protocol for a single-arm, adaptive basket trial in rheumatoid and psoriatic arthritis.","authors":"Rory Sheppard, Myrsini Gianatsi, Ian Thomas, Sophie King, David Gillespie, Philip Pallmann, Sara Marsal Barril, Ernest Choy","doi":"10.1093/rap/rkag036","DOIUrl":"10.1093/rap/rkag036","url":null,"abstract":"<p><strong>Objectives: </strong>Current treatments for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) reduce disease activity but often fail to achieve sustained remission. The Decision on Optimal Combinatorial Therapies in Immune-mediated inflammatory diseases using Systems approaches (DocTIS) program has shown that additive anti-inflammatory effects in patients with arthritis can be achieved by combining tumour necrosis factor (TNF) and interleukin (IL)-6 inhibitor therapies. The goal was to provide proof-of-principle evaluation of whether combining TNF and IL-6 inhibitors shows a signal of activity on remission outcomes in RA and PsA.</p><p><strong>Methods: </strong>This is a single-arm, multicentre, adaptive basket trial recruiting 20 patients with RA and 20 with PsA and including 24 weeks of treatment and 10 weeks of safety follow-up. Eligible participants on TNF for ≥6 weeks will proceed with the addition of IL-6 inhibitor (tocilizumab) at 162 mg every 2 weeks for 8 weeks, increasing to weekly dosing in weeks 9-24 if well tolerated. The primary outcome is remission at 24 weeks (Clinical Disease Activity Index score ≤2.8 in RA and Disease Activity in PsA score <4). Secondary outcomes include safety, tolerability and disease activity assessments. Using Simon's two-stage design (80% power, one-sided α = 0.10), the trial aims to detect an increase in remission (10% to 30%). An interim futility analysis will occur after seven participants per basket reach 24 weeks.</p><p><strong>Conclusion: </strong>Findings from this proof-of-principle study will inform the feasibility and design of future randomised trials evaluating combination biologic therapy in inflammatory arthritis.</p><p><strong>Study registration: </strong>www.isrctn.com; ISRCTN50666516.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"10 2","pages":"rkag036"},"PeriodicalIF":2.8,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13127746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147820285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}